Navigation Links
ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation
Date:3/14/2010

R3i is responding to this critically important clinical problem. 'Given the magnitude of the global epidemic of type 2 diabetes - especially in developing regions - targeting atherogenic dyslipidemia is crucial. As the only independent global research foundation focusing on this issue, the R3i is urgently developing recommendations for evidence-based strategies to reduce residual vascular risk. Currently, we are conducting the first world-wide epidemiological study, REALIST, to establish the prevalence of atherogenic dyslipidemia and consequent residual risk of cardiovascular events. Now, as a result of ACCORD Lipid, we will also initiate a meta-analysis of the atherogenic dyslipidemic subgroups of patients (high TG and/or low HDL-C) in previous fibrate studies,' said Professor Fruchart.

Notes to Editors

About ACCORD

The ACCORD study was sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH) in the U.S, and was conducted across the U.S. and Canada. The key question addressed in the ACCORD Lipid treatment arm was whether the combination of fenofibrate plus simvastatin, i.e. targeting elevated TG and low HDL-C in addition to LDL-C, was more effective in reducing cardiovascular events than statin therapy alone in a cohort of 5,518 high-ri
'/>"/>

SOURCE Residual Risk Reduction initiative (R3i)
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
2. Symmetry Medical to Present at Canaccord Adams Small-Cap Orthopedics Conference
3. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
4. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
5. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
6. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
7. C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study
8. As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloitte Report
9. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
10. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
11. Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Protocol Networks brings independent technology consulting ... brand-neutral, independent consultants, Protocol Networks has recently announced its ... the years, his company has attracted several clients in ... as well as others. With the success of these ...
(Date:1/22/2015)... WI (PRWEB) January 22, 2015 Dr. Greg ... the 12th annual Scripps Natural Supplements Pre-Conference seminar on probiotics ... Conference is an annual continuing education conference for health care ... and included the topic of probiotics in health. Dr. Leyer ...
(Date:1/22/2015)... Jersey , 22 de enero de 2015  El Dr. ... hoy su llamada a nominaciones para 2015. Este prestigioso ... hecho, o tiene el potencial para hacer, contribuciones destacadas ... se aceptarán hasta el 15 de marzo de 2015 ...
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... Feb. 9, 2011 HIGHLIGHTS:2010 Results (all percentages ... 2010 reported sales were $582 million, a new quarterly high. Q4 ... adjusted basis, respectively.  Full year 2010 sales increased 6% and 5% ... Q4 2010 reported diluted EPS was $0.76. Excluding restructuring costs ...
... YORK, Feb. 9, 2011 Reportlinker.com announces that ... its catalogue: Strategic Analysis of ... http://www.reportlinker.com/p0376721/Strategic-Analysis-of-European-Human-Machine-Interface-HMI-Market.html This research ... Europe primarily over the two broad categories of ...
... Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR ) ... release after the market closes on February 23, 2011. Due ... be hosting a conference call to discuss its fourth quarter ... Inspiration. Dedication. Innovation. ...
Cached Biology Technology:Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 3Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 4Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 5Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 6Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 7Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 8Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 9Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 10Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 11Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 12Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 13Reportlinker Adds Strategic Analysis of European Human Machine Interface (HMI) Market 2
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has ... Market 2015-2019" report to their offering. ... is a technology used for the identification of individuals. ... a person such as nose, jaw edges, mouth, and ...
(Date:12/11/2014)... blood pressure plays a role in human health has been ... for high blood pressure – was first described as a ... used in measuring blood pressure was invented in 1896. ... its triggers and its effects. In fact, recent findings have ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Attend the International Osteoporosis Foundation,s key regional meeting ... participate in an enriching scientific programme of direct ... faculty of leading experts from around the world. ... includes... Plenary sessions ...
... of more than 100 studies from around the world shows ... solvents is likely associated with a higher risk of developing ... print issue of Neurology , the medical journal of ... association, there was also a link between farming or country ...
... identified a new regulator for plant hormone signaling -- the ... help to improve production of fruits, vegetables and grains. ... 27 in the journal Proceedings of the National Academy ... controls cytokinin signaling by regulating the degradation of type-B response ...
Cached Biology News:KISS ME DEADLY proteins may help improve crop yields 2
... DNA120 is a dedicated concentrator for efficient ... of DNA/RNA. The integrated system combines the ... The compact design, automatic pump and rotor ... time; one for heater time), makes the ...
... (For small quantities of solvents with DNA ... concentrator/centrifugal evaporator systems respond to specific applications ... and safe concentration of heat-labile samples. The ... different of cold traps and a wide ...
... series of vacuum concentrators/centrifugal evaporators offers a ... to rapid and safe concentration of heat-labile ... with oil-free or high vacuum pumps, a ... selection of rotors (eliminating sample loss by ...
For relative and/or absolute quantification with standard accuracy requirements using MS or NMR instruments...
Biology Products: